Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
Actuarial Approach01:20

Actuarial Approach

The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and Cox...
Introduction To Survival Analysis01:18

Introduction To Survival Analysis

Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time until a...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

MVA-BN monkeypox vaccine safety in a clinical trial in the Democratic Republic of the Congo.

NPJ vaccines·2026
Same author

Rigid and electrode-compatible multicomponent organic crystals for piezoelectric energy harvesting.

Journal of materials chemistry. A·2026
Same author

Assessing Open-world Foundation Models for Zero-shot Skin Segmentation in Clinical Dermatological Photographs.

Proceedings of SPIE--the International Society for Optical Engineering·2026
Same author

Five-Year Outcomes for Patients With RVOT Dysfunction Treated With the SAPIEN 3 Transcatheter Heart Valve: A Pooled Analysis From the COMPASSION S3 Trial.

Circulation. Cardiovascular interventions·2026
Same author

Reflections on FDA Draft Guidance on Bayesian Methods in Trials-Protecting Scientific Integrity and Evidentiary Standards.

JAMA·2026
Same author

Response-adaptive randomization with imperfect intermediate endpoints.

Clinical trials (London, England)·2026

Related Experiment Video

Updated: Jun 5, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

An audit strategy for progression-free survival.

Lori E Dodd1, Edward L Korn, Boris Freidlin

  • 1Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland 20892, USA. doddl@mail.nih.gov

Biometrics
|January 8, 2011
PubMed
Summary

A new BICR audit strategy offers an efficient alternative to full reviews for cancer progression-free survival (PFS) in clinical trials. This method improves estimation accuracy by combining local evaluations with sampled central reviews, enhancing treatment effect assessment.

Related Experiment Videos

Last Updated: Jun 5, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Area of Science:

  • Clinical Trials Methodology
  • Biostatistics
  • Oncology Research

Background:

  • Subjective endpoints in clinical trials necessitate methods like blinded independent central review (BICR) to mitigate bias.
  • Progression-free survival (PFS) in oncology relies on image interpretation, making it susceptible to bias from local evaluations (LE).
  • The utility of complete-case BICR for time-to-event outcomes like PFS is debated.

Purpose of the Study:

  • To propose an efficient BICR audit strategy as an alternative to complete-case BICR.
  • To develop a statistical method that enhances the precision of treatment effect estimation using audited BICR data.
  • To provide assurance of treatment effect presence with reduced review burden.

Main Methods:

  • Development of an auxiliary-variable estimator for the log-hazard ratio.
  • Incorporation of data from both local evaluations (LE) and audited BICR cases.
  • Evaluation of a two-stage auditing strategy through simulation studies.

Main Results:

  • The proposed estimator is asymptotically unbiased and more efficient than using only audited BICR data.
  • Efficiency gains increase with higher correlation between local evaluations (LE) and BICR.
  • Retrospective application to an oncology trial demonstrated potential efficiency improvements.

Conclusions:

  • A BICR audit strategy can effectively provide assurance of treatment effects for PFS endpoints.
  • This approach offers significant efficiency gains compared to complete-case BICR, especially with correlated assessments.
  • The proposed methodology can optimize resource allocation in oncology clinical trials.